ENTA
Enanta Pharmaceuticals Inc
NASDAQ: ENTA · HEALTHCARE · BIOTECHNOLOGY
$13.87
+1.17% today
Updated 2026-04-29
Market cap
$386.25M
P/E ratio
—
P/S ratio
5.77x
EPS (TTM)
$-3.21
Dividend yield
—
52W range
$5 – $17
Volume
0.2M
Enanta Pharmaceuticals Inc (ENTA) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $22.76M | $41.88M | $41.71M | $32.05M | $47.74M | $160.88M | $88.27M | $102.81M | $206.63M | $205.20M | $122.47M | $97.07M | $86.16M | $79.20M | $67.64M | $65.32M |
| Revenue growth (YoY) | — | +84.0% | -0.4% | -23.1% | +48.9% | +237.0% | -45.1% | +16.5% | +101.0% | -0.7% | -40.3% | -20.7% | -11.2% | -8.1% | -14.6% | -3.4% |
| Cost of revenue | — | $16.08M | $20.25M | $22.80M | $28.76M | $36.09M | $55.77M | $76.06M | $115.78M | — | — | — | $2.97M | $2.37M | — | $4.59M |
| Gross profit | $22.76M | $41.88M | $41.71M | $32.05M | $47.74M | $160.88M | $88.27M | $102.81M | $206.63M | $205.20M | $122.47M | $97.07M | $86.16M | $79.20M | $67.64M | $60.74M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 93.0% |
| R&D | $9.72M | $11.55M | $15.12M | $16.84M | $18.74M | $23.19M | $40.46M | $57.45M | $94.86M | $142.21M | $136.76M | $174.11M | $164.52M | $163.52M | $131.48M | $106.74M |
| SG&A | $6.11M | — | $5.30M | $6.18M | $10.02M | $13.54M | $16.97M | $20.75M | $23.44M | $26.25M | $27.36M | $32.54M | $45.48M | $52.89M | $57.85M | $43.93M |
| Operating income | $6.94M | $25.30M | $21.29M | $9.03M | $18.98M | $124.15M | $30.84M | $24.61M | $88.33M | $36.74M | $-41.64M | $-109.57M | $-123.84M | $-137.21M | $-121.69M | $-85.35M |
| Operating margin | 30.5% | 60.4% | 51.0% | 28.2% | 39.8% | 77.2% | 34.9% | 23.9% | 42.7% | 17.9% | -34.0% | -112.9% | -143.7% | -173.2% | -179.9% | -130.7% |
| EBITDA | $8.30M | $26.97M | $21.57M | $9.25M | $19.34M | $124.79M | $32.50M | $26.75M | $90.85M | $40.00M | $-37.99M | $-106.24M | $-119.22M | $-123.48M | $-104.51M | $-70.78M |
| EBITDA margin | 36.5% | 64.4% | 51.7% | 28.9% | 40.5% | 77.6% | 36.8% | 26.0% | 44.0% | 19.5% | -31.0% | -109.4% | -138.4% | -155.9% | -154.5% | -108.4% |
| EBIT | $7.75M | $26.47M | $21.40M | $9.03M | $18.98M | $124.15M | $30.84M | $24.61M | $88.33M | $36.74M | $-41.64M | $-109.57M | $-122.19M | $-125.85M | $-106.85M | $-75.87M |
| Interest expense | $0.00 | $3.16M | $0.00 | $31000.00 | $18000.00 | $8000.00 | $45000.00 | $40000.00 | $4.85M | $8.82M | $10.26M | $5.33M | $1.57M | $5.15M | $10.94M | $7.68M |
| Income tax | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $7.90M | $23.31M | $21.40M | $9.63M | $34.44M | $78.99M | $21.67M | $17.71M | $71.96M | $46.38M | $-36.17M | $-79.00M | $-121.75M | $-133.82M | $-116.05M | $-81.89M |
| Net income growth (YoY) | — | +194.9% | -8.2% | -55.0% | +257.7% | +129.4% | -72.6% | -18.3% | +306.3% | -35.5% | -178.0% | -118.4% | -54.1% | -9.9% | +13.3% | +29.4% |
| Profit margin | 34.7% | 55.7% | 51.3% | 30.0% | 72.1% | 49.1% | 24.5% | 17.2% | 34.8% | 22.6% | -29.5% | -81.4% | -141.3% | -169.0% | -171.6% | -125.4% |